Literature DB >> 16291014

Pharmacokinetic interactions between statins and fibrates.

Alberto Corsini1, Stefano Bellosta, Michael H Davidson.   

Abstract

Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291014     DOI: 10.1016/j.amjcard.2005.08.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.

Authors:  Alberto Corsini; Nicola Ferri; Marco Proietti; Giuseppe Boriani
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

Review 2.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

3.  The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus.

Authors:  Marshall Elam; Laura Lovato; Henry Ginsberg
Journal:  Clin Lipidol       Date:  2011

4.  Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.

Authors:  Michel Farnier; David Marcereuil; Sophie De Niet; Jean Ducobu; Armin Steinmetz; Kjetil Retterstøl; Leszek Bryniarski; Albert Császár; Francis Vanderbist
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

Review 5.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 6.  ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.

Authors:  Arzu Kalayci; C Michael Gibson; Paul M Ridker; Samuel D Wright; Bronwyn A Kingwell; Serge Korjian; Gerald Chi; Jane J Lee; Pierluigi Tricoci; S Hassan Kazmi; Clara Fitzgerald; Alka Shaunik; Gail Berman; Danielle Duffy; Peter Libby
Journal:  Curr Atheroscler Rep       Date:  2022-05-07       Impact factor: 5.967

7.  Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects.

Authors:  Omar Patiño-Rodríguez; Rosa María Martínez-Medina; Irma Torres-Roque; Maricela Martínez-Delgado; América Susana Mares-García; Abraham Escobedo-Moratilla; Amador Covarrubias-Pinedo; Angélica Arzola-Paniagua; José Luis Herrera-Torres; José Pérez-Urizar
Journal:  Front Pharmacol       Date:  2015-01-29       Impact factor: 5.810

Review 8.  PPAR Agonists and Metabolic Syndrome: An Established Role?

Authors:  Margherita Botta; Matteo Audano; Amirhossein Sahebkar; Cesare R Sirtori; Nico Mitro; Massimiliano Ruscica
Journal:  Int J Mol Sci       Date:  2018-04-14       Impact factor: 5.923

9.  Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways.

Authors:  Andrea László; László Kalabay; János Nemcsik
Journal:  BMC Res Notes       Date:  2013-02-06

Review 10.  Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.

Authors:  Michel Farnier
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.